1. Home
  2. TGTX

as of 11-18-2026 10:28am EST

$64.36
+$1.65
+2.63%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.

Founded: 1993 Country:
United States
United States
Employees: N/A City: NEW YORK
Market Cap: 8.5B IPO Year: 2008
Target Price: $69.43 AVG Volume (30 days): 1.8M
Analyst Decision: Buy Number of Analysts: 8
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: 0.52 EPS Growth: 1746.67
52 Week Low/High: $26.76 - $68.03 Next Earning Date: 11-09-2026
Revenue: $2,785,000 Revenue Growth: -58.36%
Revenue Growth (this year): 61.95% Revenue Growth (next year): 35.55%
P/E Ratio: 120.60 Index:
Free Cash Flow: -24986000.0 FCF Growth: N/A

Stock Insider Trading Activity of TG Therapeutics Inc. (TGTX)

Sell
TGTX Sep 10, 2026

Avg Cost/Share

$54.96

Shares

5,000

Total Value

$274,800.00

Owned After

168,640

SEC Form 4

Earnings Transcripts

SEC 8-K filings with transcript text

View All
2026
Q3

Q3 2026 Earnings

8-K SELL

Nov 9, 2026 · 100% conf.

AI Prediction SELL

1D

-5.76%

$59.22

Act: +1.85%

5D

-11.21%

$55.80

20D

-5.08%

$59.65

Price: $62.84 Prob +5D: 0% AUC: 1.000
0001628280-26-071870

EX-99.1

2 q3-26earningsprxexx991.htm

EX-99.1

Document

Exhibit 99.1

TG Therapeutics Reports Third Quarter 2026 Financial Results and Raises Full-Year Revenue Guidance

Raises full-year 2026 total global revenue guidance to approximately $1 billion, from approximately $950 million

Raises full-year 2026 BRIUMVI U.S. net product revenue guidance to approximately $915–920 million, from $890–905 million

Third-quarter 2026 total global revenue of approximately $260 million, including approximately $233 million in BRIUMVI U.S. net product revenue

MSToronto2026 presentations highlight seven-year BRIUMVI efficacy and safety follow-up, positive ENHANCE results supporting BRIUMVI single-infusion initiation, and progress toward quarterly self-administered subcutaneous treatment

Conference call to be held today, Monday, November 9, 2026, at 8:30 AM ET

New York, NY, (November 9, 2026) – TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the third quarter of 2026, along with recent company developments and provided an update on 2026 financial guidance.

Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics, stated, “With solid third-quarter performance and a strong fourth quarter anticipated, we are on track to exceed $1 billion in global revenue in 2026, less than four years after launching BRIUMVI. With continued momentum in our IV business, the potential to expand the BRIUMVI franchise through new dosing options, and a growing pipeline of development opportunities, we believe we are laying the foundation for sustained, long-term growth. The compelling clinical data presented at MSToronto2026 provide further support for the substantial opportunities we see ahead.”

Mr. Weiss continued, “Looking ahead, we see a series of important catalysts over the next 18 to 24 months, including pivotal Phase 3 subcutaneous BRIUMVI results expected around year-end or early 2027, a potential launch of simplified IV initiation in mid-2027, additional clinical data from our expanding pipeline, and a potential subcutaneous BRIUMVI launch in 2028. Our increased full-year revenue guidance reflects the continued strength of our commercial business, while the approximately $100 million of shares repurchased during the quarter underscores our confidence in TG's long-term value.”

Recent Highlights & Developments

BRIUMVI® (ublituximab-xiiy) Commercialization

•BRIUMVI U.S. net product revenue of $232.6 million for the third quarter 2026, representing approximately a 52% increase over the same period last year

•Total global revenue of $259.9 million for the third quarter 2026

Clinical Data Highlights from MSToronto2026, the 10th Joint ACTRIMS-ECTRIMS Meeting

•Phase 3 ENHANCE Trial: Positive Phase 3 results demonstrated bioequivalent drug exposure between the currently approved two-infusion BRIUMVI initiation regimen and a consolidated single 600mg initiation infusion. Infusion-related reactions were comparable between regimens, with no Grade 3 or higher reactions observed, supporting the potential for a simplified treatment initiation schedule.

•Phase 1 Subcutaneous BRIUMVI (ublituximab) Trial: Positive Phase 1 data demonstrated mean bioavailability greater than 60% relative to IV administration, with pharmacokinetic modeling supporting the quarterly dosing regimen being evaluated in the fully enrolled Phase 3 trial. Top-line Phase 3 data are expected by year-end 2026 or early 2027.

•Seven-Year Follow-up Data from the ULTIMATE I & II Phase 3 Trials: BRIUMVI demonstrated sustained efficacy with an annualized relapse rate (ARR) of 0.018 in the seventh year of treatment and 88.3% of continuously treated patients remaining free from 24-week confirmed disability progression. Patients receiving continuous BRIUMVI treatment experienced lower rates of disability progression than those who switched from teriflunomide, with a consistent long-term safety profile.

•Phase 4 ENABLE Real-World Study: Updated data from 1,076 participants, 30% of whom switched from prior CD20 therapy, showed that 99.2% remained relapse-free during BRIUMVI treatment, with an ARR of 0.014. First-dose infusion-related reactions occurred in 18.8% of participants, and median subsequent infusion times of 63 minutes supported the one-hour infusion experience in clinical practice.

•Phase 1 Azer-cel in Progressive MS Trial: Initial data demonstrated an encouraging safety profile in 26 participants, with no dose-limiting or high-grade CAR T-associated toxicities observed. Despite prior disease progression, 89% of evaluable participants had stable or improved disability scores at Day 90 and 88% at Day 180, with longer-term follow-up ongoing.

BRIUMVI in Myasthenia Gravis

•Announced positive topline phase 1 data for subcutaneous BRIUMVI in patients with myasthenia gravis (MG)

•Initiated a potentially registration-directed randomized phase 2 clinical trial evaluating IV BRIUMVI as a maintenance t

2026
Q2

Q2 2026 Earnings

8-K SELL

Aug 3, 2026 · 100% conf.

AI Prediction SELL

1D

-5.87%

$48.98

Act: +5.56%

5D

-11.21%

$46.20

20D

-5.08%

$49.39

Price: $52.03 Prob +5D: 0% AUC: 1.000
0001437749-26-025304

SEC.gov | Request Rate Threshold Exceeded

U.S. Securities and Exchange Commission

You’ve Exceeded the SEC’s Traffic Limit

Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.

Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.

The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.

For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.

For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.

Reference ID: 0.c706d217.1785760620.94f22718

More Information

Internet Security Policy

By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.

Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).

To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.

If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.

Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.

Note: We do not offer technical support for developing or debugging scripted downloading processes.

2026
Q1

Q1 2026 Earnings

8-K BUY

May 6, 2026 · 100% conf.

AI Prediction BUY

1D

+2.14%

$42.87

Act: +2.51%

5D

+14.39%

$48.01

Act: +1.62%

20D

+19.46%

$50.14

Act: -3.36%

Price: $41.97 Prob +5D: 100% AUC: 1.000
0001437749-26-015013

SEC.gov | Request Rate Threshold Exceeded

U.S. Securities and Exchange Commission

You’ve Exceeded the SEC’s Traffic Limit

Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.

Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.

The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.

For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.

For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.

Reference ID: 0.c706d217.1784334080.ccd2b565

More Information

Internet Security Policy

By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.

Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).

To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.

If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.

Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.

Note: We do not offer technical support for developing or debugging scripted downloading processes.

Share on Social Networks: